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Chapter 4.1: Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium
Kidney International (2010) 78, 1191; doi:10.1038/ki.2010.371
Correction to: Kidney International (2009) 76 (Suppl 113), S50–S99; doi:10.1038/ki.2009.192
The formulations for sevelamer-HCl, sevelamer carbonate, and lanthanum carbonate were incorrectly stated. Both
sevelamer-HCl and sevelamer carbonate are available in tablet forms and lanthanum carbonate is available as a chewable
tablet in four dosages (250, 500, 750, and 1000 mg). Content for magnesium carbonate should read: approximately 28%
Mg2þ (85 mg) per total MgCO3, not per total mg carbonate as originally given. The revised entries are in bold and italic.
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Table 19 | Phosphate-binding compounds
Binder source Rx Forms
Content
(mineral/metal/element) Potential advantages Potential disadvantages
Aluminum hydroxide No Liquid, tablet, capsule Aluminum content varies from
100 to 4200mg (per tablet)
Very effective phosphate-binding
capacity; variety of forms
Potential for aluminum toxicity;
altered bone mineralization,
dementia; GI side effects
Calcium acetate Yes/no Capsule, tablet Contains 25% elemental Ca2+
(169mg elemental Ca2+ per
667mg cap)
Effective phosphate-binding,
potentially for enhanced
phosphate-binding capability
over CaCO3 potentially less
calcium absorption
Potential for hypercalcemia-
associated risks including
extraskeletal calcification and
PTH suppression; more costly
than CaCO3; GI side effects
Calcium carbonate No Liquid, tablet, chewable,
capsule, gum
Contains 40% elemental Ca2+
(200mg elemental Ca2+ per
500mg CaCO3)
Effective, inexpensive, readily
available
Potential for hypercalcemia-
associated risks including
extraskeletal calcification and
PTH suppression; GI side effects
Calcium citrate No Tablet, liquid, capsule Contains 22% elemental Ca2+ Not recommended in CKD Enhancement of aluminum
absorption; GI side effects
Calcium ketoglutarate Similar to other calcium salts,
costly, GI side effects, potentially
less hypercalcemic than calcium
carbonate or acetate, not well
studied
Calcium gluconate Tablet, powder Similar to other calcium salts,
not well studied
Ferric citrate GI side effects, not well studied
Magnesium/calcium
carbonate
No Tablet Approximately 28% Mg2+
(85mg) per total MgCO3 and
25% elemental Ca2+ (100mg)
per total CaCO3
Effective; potential for lower
calcium load than pure
calcium-based binders
GI side effects, potential for
hypermagnesemia, not well
studied
Magnesium carbonate/
calcium acetate
Yes Tablet Lack of availability worldwide;
assumed to have similar effects
of its components
Sevelamer-HCl Yes Tablet None Effective; no calcium/metal; not
absorbed; potential for reduced
coronary/aortic calcification when
compared with calcium-based
binders in some studies; reduces
plasma concentration of LDL-C
Cost; potential for decreased
bicarbonate levels; may require
calcium supplement in presence
of hypocalcemia; GI side effects
Sevelamer carbonate Yes Tablet, powder None Effective; no calcium/metal; not
absorbed; assumed to have similar
advantages as sevelamer-HCl;
potentially improved acid-base
balance
Cost; may require calcium
supplement in the presence of
hypocalcemia; GI side effects
Lanthanum carbonate Yes Tablet, chewable Contains 250, 500, 750, or
1000mg elemental
lanthanum per tablet
Effective; no calcium; chewable Cost; potential for accumulation
of lanthanum due to GI
absorption, although long-term
clinical consequences unknown;
GI side effects
Abbreviations: CKD, chronic kidney disease; GI, gastrointestinal; LDL-C, low-density lipoprotein cholesterol; PTH, parathyroid hormone.
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